Actively Recruiting
Open Multicenter Study of Oral TQ05105 Tablets for Treating Moderate to Severe Chronic Graft-versus-host Disease
Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2026-08-26
65
Participants Needed
12
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of TQ05105 Tablets in adults with moderate to severe chronic graft-versus-host disease cGVHD. This open, multi-center Phase II clinical trial focuses on patients who have already received systemic treatments for cGVHD and aims to assess how well this new oral medication works to reduce disease symptoms and improve patient outcomes. Participants will take TQ05105 Tablets twice daily in 28-day treatment cycles. TQ05105 is an oral drug that targets specific pathways involved in inflammation and fibrosis associated with cGVHD. The trial will monitor patients up to 24 weeks for the main response rate and continue follow-up for up to 96 weeks to evaluate longer-term effects, including survival and safety outcomes. During the study, participants will have regular assessments to measure treatment response, side effects, blood counts, and organ function. Researchers will track objective responses, duration of response, survival rates, and adverse events. Participants are expected to be involved in these evaluations for up to two years, allowing for thorough monitoring of the drugs impact and safety over time.
CONDITIONS
Brief Title
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
Research Team
H
He Huang, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here